• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We're Reading: Budget and Opioids; FDA Chief Balancing Act; New Drug Czar


The White House budget set for release Monday will include almost $17 billion to fight opioid addiction; a profile of FDA chief Scott Gottlieb, MD, describes him as someone who's become adept at balancing competing interests; the Trump administration is set to appoint a new drug czar with no public health experience.

White House Budget to Include Almost $17 Billion to Battle Opioids

The White House’s fiscal 2019 budget set to be released Monday will include nearly $17 billion for the opioid epidemic, The Hill reported. HHS will received the bulk of the money to expand prevention, treatment, recovery and mental health services—$3 billion for 2018 and $10 billion for 2019.

FDA Chief Balancing Interests in Conventional Way, Winning Over Some Skeptics

Scott Gottlieb, MD, is approaching his FDA job as chief of the agency in a more conventional way than other administration appointees, The New York Times reported this weekend. He is keeping both the president and industry supporters satisfied while also quieting some skeptics, and is trying to balance protecting public health while also offering rewards to industry.

National Drug Office Set to Get New Policy Chief

The While House deputy chief of staff, an attorney with no public health experience, is slated to become the next head of the Office of National Drug Control Policy, STAT reported. Jim Carroll would serve as the administration’s next drug czar. In related news, health advocates are waiting to see if the office is still slated to see its budget cut 95% in the administration’s upcoming budget.

Related Videos
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Video 1 - "Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers"
Landman family
Related Content
© 2023 MJH Life Sciences
All rights reserved.